By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation dedicated to ending childhood cancer by driving targeted and innovative research, has officially announced the appointment of Osama Alsaleh to its Board of Directors. This strategic addition comes at a pivotal moment for the organization as it seeks to bridge the critical gap between early-stage laboratory research and the commercial development of life-saving pediatric treatments. Alsaleh, a distinguished executive with a deep background in venture capital, health equity, and global healthcare technology, brings a unique set of skills designed to catalyze investment and technological integration in a field that has historically been underserved by traditional pharmaceutical markets.
As the current Head of Partnerships at Plug and Play Health—the healthcare arm of one of the world’s most active venture capital firms and global innovation platforms—Alsaleh is positioned at the intersection of emerging technology and institutional healthcare. His appointment to the CureSearch board is intended to leverage this vantage point to attract new stakeholders to the pediatric oncology space, including tech startups, private equity investors, and multinational healthcare corporations.
A Career Defined by Innovation and Strategic Collaboration
The professional trajectory of Osama Alsaleh reflects a consistent focus on systemic healthcare transformation. Before his leadership role at Plug and Play Health, Alsaleh held several high-impact positions at Oracle Health (formerly Cerner Corporation), where his work spanned clinical decision-making, regulatory compliance, and the development of health equity frameworks.
During his tenure at Oracle, Alsaleh was instrumental in establishing the company’s health equity team. This initiative was designed to address the social determinants of health (SDoH) through data-driven strategies, ensuring that medical technological advancements were accessible to marginalized and underrepresented populations. His work in this area aligns closely with CureSearch’s mission to ensure that all children, regardless of socioeconomic background, have access to the latest advancements in cancer therapy.
Furthermore, Alsaleh’s experience in financial stewardship within the healthcare sector is extensive. He previously served on the Oracle Charitable Foundation’s Clinical Decision Committee, where he contributed to the evaluation and strategic allocation of over $42 million in healthcare grants. This experience in grant-making and outcome-based funding provides him with a rigorous framework for evaluating CureSearch’s research portfolio, which focuses on projects with the highest potential for clinical impact.
His influence also extends into the public sector and international policy. Alsaleh has served as a consultant and advisor to major global entities, including the World Bank Group and the World Health Organization (WHO). In the United States, his expertise was sought by the White House COVID-19 Taskforce and the US State Department, where he collaborated on regulatory measures and quality reporting initiatives with the Centers for Medicare & Medicaid Services (CMS).
The Landscape of Pediatric Cancer Research and Funding
The appointment of a venture capital specialist like Alsaleh highlights a significant challenge within the oncology sector: the "pediatric gap." While adult cancer research often attracts massive private investment due to the large patient populations and potential for high returns, pediatric cancer is frequently classified as a "rare disease" market.
According to data from the National Cancer Institute (NCI), although cancer remains the leading cause of death by disease among children in the United States, only a small fraction of federal oncology funding is dedicated specifically to pediatric research. Historically, this has hovered around 4% of the NCI’s total budget. Furthermore, because the total number of pediatric cancer cases is significantly lower than adult cases (approximately 15,000 new diagnoses per year in the U.S. compared to nearly 2 million adult cases), pharmaceutical companies often find it difficult to justify the high costs of drug development—estimated at over $2.5 billion per new molecular entity—for the pediatric market.
CureSearch has sought to address this "market failure" through a model known as venture philanthropy. By funding high-potential research that is too advanced for basic science grants but too early for private equity, CureSearch de-risks the development process, making it more attractive for commercial partners to step in and bring drugs to market. Alsaleh’s expertise is expected to enhance this model by identifying "dual-use" technologies that might have been developed for adult indications but could be pivoted for pediatric use.
Chronology of Leadership and Board Evolution
The inclusion of Alsaleh is part of a multi-year effort by CureSearch to diversify its board beyond clinical oncology and traditional philanthropy.
- 2021-2022: CureSearch expanded its focus on "Catapult Awards," designed to move research from the lab into Phase I clinical trials.
- 2023: The organization intensified its search for board members with deep ties to the Silicon Valley innovation ecosystem to better understand how AI and machine learning could accelerate drug discovery.
- 2024 (Early): Jared Brancazio was appointed Chair of the Board of Directors, signaling a shift toward aggressive strategic growth.
- Current Appointment: Osama Alsaleh joins the board, specifically tasked with bridging the gap between the non-profit mission and the venture capital world.
Official Responses and Strategic Vision
Leadership at CureSearch has expressed high expectations for the impact Alsaleh will have on the organization’s ability to scale its operations. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the importance of Alsaleh’s multifaceted background.
"Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
For Alsaleh, the motivation to join the board is rooted in a desire to correct the systemic underrepresentation of pediatric needs in the broader tech and investment landscape. He noted that while the "Age of AI" and biotech innovation is booming, children often remain an afterthought in the development cycle.
"Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh said. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Broader Impact and Industry Implications
The integration of a venture capital executive into a pediatric cancer non-profit reflects a broader trend in the healthcare industry: the rise of "strategic philanthropy." In this model, non-profits no longer act solely as donors but as active participants in the biotech ecosystem.
Alsaleh’s presence on the board is likely to influence several key areas:
- Accelerated Tech Adoption: Pediatric oncology research often relies on fragmented data sets due to the rarity of the diseases. Alsaleh’s experience with Oracle and Plug and Play could facilitate the adoption of advanced data-sharing platforms and AI-driven predictive modeling to identify effective drug targets more quickly.
- Global Partnership Development: With his background at the World Bank and WHO, Alsaleh is well-positioned to help CureSearch expand its influence beyond North America, fostering international collaborations that can increase the size of clinical trial cohorts.
- Investment De-risking: By bringing a "VC lens" to the board, Alsaleh can help CureSearch identify which research projects have the highest "commercial "readiness," ensuring that donor dollars are used to fund projects that have a viable path to FDA approval and widespread clinical use.
- Regulatory Navigation: His past work with the US State Department and CMS will be invaluable as CureSearch navigates the complexities of the Research to Accelerate Cures and Equity (RACE) for Children Act. This federal law requires companies developing adult cancer drugs to also evaluate those drugs in children if the molecular targets are relevant to a pediatric cancer.
Statistical Context: The Urgent Need for New Treatments
While survival rates for some childhood cancers, such as certain types of leukemia, have improved significantly over the last few decades, others remain nearly 100% fatal. For example, Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive brain tumor, has seen little change in prognosis in over 30 years.
- Survival Disparity: While the overall five-year survival rate for childhood cancer is 85%, this number masks the reality that many survivors suffer from lifelong "late effects" caused by the toxicity of current treatments, including secondary cancers, heart disease, and cognitive impairments.
- Treatment Scarcity: Since 1978, the FDA has approved significantly fewer drugs specifically for pediatric cancer compared to adult cancers. Most children are treated with "off-label" drugs developed for adults, which were not designed for developing bodies.
- Economic Burden: Pediatric cancer is the leading cause of bankruptcy among families with a sick child in the U.S., highlighting the need for more efficient drug development that reduces costs for the healthcare system and families alike.
The addition of Osama Alsaleh to the CureSearch Board of Directors represents a modern approach to solving these entrenched problems. By combining the heart of a non-profit mission with the strategic rigor of the venture capital and technology sectors, CureSearch aims to rewrite the narrative for children facing a cancer diagnosis. His role will be instrumental in ensuring that the next generation of oncology breakthroughs is not just a possibility, but a reality for pediatric patients worldwide.
